AzTrials
AzTrials

Urinary Tract InfectionsPRO30CSPNCT05513677

Characterisation of Biofilm Growth on Coated vs. Uncoated Urinary Catheter Surfaces in Normal Clinical Use

A study testing M4D in people with Urinary Tract Infections, run by Camstent Ltd. at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

1. Evaluated Patients: 5 patients (Convenience sample: non-blinded, non-randomised) Selection follows documented hospital protocols for routine catheterisation 2. Measured Patients: 30 patients (Convenience sample: non-blinded and non-randomised) 20 who receive the M4D coated catheter. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Urinary Tract Infections
What is being tested?
M4D
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
35 participants
Where
1 siteUnited Kingdom
Study dates
14 Aug 2018to 30 Dec 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • -

Who cannot join

  • • Patients under age 18.
  • Patients that have or recently (within 3 weeks) had a urinary catheter, or those with signs of current urinary tract infection.
  • Patients who they have had previous radiation therapy in lower pelvis.
  • Patients who are cognitively impaired, or are unwilling to give consent
  • Patients with a potentially immunocompromised condition
  • Patients that require further antibiotics after initial dose, or those that are administered antibiotics following an infection whilst the trial urinary catheter is in situ

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • The James Cook University Hospital,

    Middlesbrough, TS4 3BW

Other trials in United Kingdom

About this study

  1. Evaluated Patients: 5 patients (Convenience sample: non-blinded, non-randomised) Selection follows documented hospital protocols for routine catheterisation
  2. Measured Patients: 30 patients (Convenience sample: non-blinded and non-randomised)
  • 20 who receive the M4D coated catheter.
  • 10 who receive the standard uncoated catheters used in routine patient care.
Read the detailed description
  1. Evaluated Patients: 5 patients (Convenience sample: non-blinded, non-randomised) Selection follows documented hospital protocols for routine catheterisation
  2. Measured Patients: 30 patients (Convenience sample: non-blinded and non-randomised)
  • 20 who receive the M4D coated catheter.
  • 10 who receive the standard uncoated catheters used in routine patient care.
  1. Evaluation (5 patients, coated catheter)

A convenience sample of patients will be selected to receive the Camstent coated catheter for their routine care. These enrolments are drawn from among those recommended for routine catheterisation, for up to 28 days and in accordance to existing hospital protocols. There is no change to the routine protocols for insertion, maintenance, withdrawal, or documentation of the patient's catheterisation. Following use, the catheter is discarded according to the hospital's procedures.

Staff questionnaires will be completed to capture general use information. These will document the opinions of the nurse inserting and withdrawing the catheter, and may include questions for the patient, to record their experience. There will be no collection of patient information, and no analysis of the discarded catheter.

  1. Measurement (10 patients receiving uncoated catheters, 20 patients receiving coated catheters)

The data collection will include 10 patients who have received the standard hospital issued uncoated catheter and 20 patients who have received the Camstent coated catheter. There will be no randomisation and no blinding.

The first 10 patients needing routine urinary catheterisation to drain their bladder for up to 28 days whilst in hospital will receive the routine hospital issued catheter and will looked after by hospital and staff as standard practice.

The next 20 patients needing routine urinary catheterisation to drain their bladder whilst in hospital will receive a coated catheter. There will be no change to the intended use of the catheter for patients where it is deemed medically necessary to drain urine from the urinary bladder via the urethra using the catheter device for up to 28 days. There will be no change to any patient care or catheterisation procedures.

All 30 catheters will be sent to a laboratory for surface examination rather than immediately disposed of as medical waste. Harvested catheters will be bagged in an airtight plastic bag and tagged with a record identifier. A record identifier will be used to establish catheter traceability and duration, and will not compromise patient anonymity. The catheter will be kept refrigerated and transported to the analysis laboratory at Nottingham University within two days.

At the Nottingham Laboratory, the catheters will be subjected to qualitative and quantitative analysis to determine the percentage of biofilm coverage on the surface. This will initially be achieved using staining followed by microscopic visual examination of the catheter surface, and images taken of any surface encrustation.

For Fluorescence Microscopy, the procedure will be:

  1. Cut the catheter into segments then wash three times in ~15 ml of PBS with gentle agitation.
  2. Transfer the washed catheter segments into the wells of a sterile 24 well plate and stain with SYTO17 Red Fluorescent Nucleic Acid Stain.
  3. Segments will be imaged using a laser scanning confocal microscope using a 10 X objective lens over a 1024 μm x 1024 μm area.
  4. A z-section will be imaged (each section is 4μm apart with 36 images taken over 140μm) such that the entire curved surface is imaged. The coverage data will then be taken from a maximum intensity z-projection.
  5. Data analysis will be carried out in ImageJ using the maximum intensity z-projection images.
  6. Images will be converted to 8-bit greyscale images, a threshold applied to select the data correctly and the biofilm coverage measured.
  7. The percentage of coverage for each sample will be computed as (Light) / (Light + Dark) * 100%.

Aggregate descriptive statistics will be calculated, and biofilm coverage will be plotted against the duration of catheterisation as a scattergram. The study is not powered to permit statistical analysis.

Prior laboratory experiments predict that the difference in biofilm coverage could exceed 80%. If larger differences are seen in harvested catheters, then a Total Cell Count assay, in which the biofilm is sonicated free of the surface and then assessed through serial dilution, may be substituted for Fluorescence Microscopy.

Being tested
M4D, Standard of Care
Medical subject headings
Urinary Tract Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • M4DDevice

    Coated catheter

  • Standard of CareDevice

    Standard of Care

Study groups in NCT05513677
Study groupRoleWhat they receive
Standard of CareActive comparatorStandard of Care
Receives: Device: Standard of Care
M4D coated catheterExperimentalExperimental
Receives: Device: M4D

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The primary outcome is the percentage of catheter surface colonised by biofilm, calculated as (light / (light + dark) x 100% in measurement of stained samples using fluorescence microscopy.

    The primary outcome is the percentage of catheter surface colonised by biofilm, calculated as (light / (light + dark) x 100% in measurement of stained samples using fluorescence microscopy.

    Measured: 30 days

Secondary outcomes (1)
  1. Secondary outcomes will be logging of events, including catheter blockage or presumed CAUTI.

    Secondary outcomes will be logging of events, including catheter blockage or presumed CAUTI.

    Measured: 30days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Aug 2022
  2. Study start14 Aug 2018
  3. Primary completion20 May 2020
  4. Study completion30 Dec 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Non-randomised
Intervention model
Single group
Model description
1. Evaluated Patients: 5 patients (Convenience sample: non-blinded, non-randomised) Selection follows documented hospital protocols for routine catheterisation 2. Measured Patients: 30 patients (Convenience sample: non-blinded and non-randomised) * 20 who receive the M4D coated catheter. * 10 who receive the standard uncoated catheters used in routine patient care.
Masking
None (open label)
Enrolment
35 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05513677
Sponsor's protocol ID
PRO30CSP
Acronym
PRO30CSP
Status last verified
Aug 2022
First submitted
22 Aug 2022
Last updated
31 Aug 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing M4D in people with Urinary Tract Infections, run by Camstent Ltd. at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The primary outcome is the percentage of catheter surface colonised by biofilm, calculated as (light / (light + dark) x 100% in measurement of stained samples using fluorescence microscopy. (time frame: 30 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in